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SUMMARY
When dealing with surgical patients, a perioperative evaluation is essential to anticipate 
complications and institute measures to reduce the risks. Several algorithms and exams 
have been used to identify postoperative cardiovascular events, which account for more 
than 50% of perioperative mortality. However, they are far from ideal. Some of these 
algorithms and exams were proposed before important advances in cardiology, at a time 
when pharmacological risk reduction strategies for surgical patients were not available. 
New biomarkers and exams, such as C-reactive protein, brain natriuretic peptide, and 
multislice computed tomography have been used in cardiology and have provided im-
portant prognostic information. The ankle-brachial index is another significant marker 
of atherosclerosis. However, specific information regarding the perioperative context of 
all these methods is still needed. The objective of this article is to evaluate cardiovascular 
risk prediction models after noncardiac surgery.
Keywords: Perioperative care; general surgery; brain natriuretic peptide; general anes-
thesia; cardiovascular risk; ankle-brachial index.
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INTRODUCTION
Perioperative evaluation is an important step before re-
ferring a patient to surgery. The purpose is not just clear-
ance for surgery, but to perform an overall evaluation of 
the clinical status, make recommendations, deal with car-
diovascular risk factors or cardiac problems, and estimate 
the procedure’s risk. Thereupon the medical team and pa-
tient can decide the best way to minimize complications, 
or even to postpone the operation1. In addition to clinical 
experience and common sense, algorithms for periopera-
tive evaluation have been proposed, tested, and validated 
to contribute to this decision. In general, sensitivity and 
specificity are quite similar among algorithms; however, 
they are unfortunately only somewhat better than a coin 
toss. In addition, most of the assessments have been based 
upon clinical characteristics of patients submitted to sur-
gery over ten years prior. More recent perioperative evalu-
ation guidelines include flowcharts suggesting tests or 
pharmacological interventions that may be a rather frus-
trating support for the algorithms, although much more 
acceptable to attending physicians.
On the other hand, population growth, developing 
countries’ welfare, technological improvement, new sur-
gical techniques allied to new materials and devices, and 
faster non-invasive strategies have led to an increase in the 
number of surgeries2,3. Indeed, patients previously consid-
ered non-candidates for surgery may now have renewed 
hope. Consequently, a larger number of patients older 
than 75 years are being referred to surgery involving mul-
tiple cardiovascular risk factors bringing about increased 
postoperative mortality and duration of hospitalization4. 
Recent predictions estimate that, from 2010 to 2040, the 
aging population in the United States will increase the in-
cidence of coronary heart disease by approximately 26%, 
as well as the costs related to care by 41%5. It is estimated 
that more than 40 million surgeries are performed annu-
ally in Europe6, and 240 million around the world7. In de-
veloping countries, the same scenario is observed. From 
1997 to 2007, an increase of 20.42% was observed in the 
number of surgical procedures in Brazil2. In the last few 
years, however, the same authors observed a 30% increase 
in the number of case-fatalities2. Whether coincident or 
related events, both findings represent important challeng-
es: how to anticipate and prevent the increase in periop-
erative complications in this apparently higher risk popu-
lation without imposing a great economic burden?
CARDIOVASCULAR COMPLICATIONS AND PERIOPERATIVE  
ALGORITHMS
Cardiovascular complications are of special concern when 
dealing with surgical patients, since approximately 1% 
of them present with acute myocardial infarction (AMI) 
after the procedure. Generally it is associated with other 
noncardiac events with an odds ratio > 6, significantly in-
creasing duration of hospitalization8. Related cardiovascu-
lar mortality reaches 0.3% (1.2 million patients in Europe 
alone), accounting for more than 50% of postoperative 
deaths after vascular surgeries6,9.
Perioperative cardiovascular risk can be estimated by 
assessing clinical status, functional capacity and intrinsic 
risk of the surgery3. However, sometimes it may be very 
difficult to estimate this risk in patients with subclinical 
presentation of diseases.
Methods and algorithms were developed some time 
ago, and are being used in clinical practice with a high 
frequency10-12. However, some of these algorithms were 
proposed prior to the development of important advanc-
es in cardiology such as the use of aspirin and statins for 
coronary artery disease and acute coronary syndromes13-19. 
They were also developed before important pharmacologi-
cal risk reduction strategies were available for surgical pa-
tients, such as beta-blockers and statins20-22. Despite hav-
ing been cautiously validated in the past, it remains to be 
investigated whether these algorithms are still applicable 
in different populations submitted to different treatments. 
Do they continue to merit confidence? Do they predict 
cardiovascular events or are they little better than as toss-
ing a coin?
The American Society of Anesthesiologists (ASA) clas-
sification was first described in 194123 and revised in 1963 
(Box 1). It was the first attempt to predict surgical com-
plications and is still, by far, the most often used by an-
esthesiologists. No other preoperative index has achieved 
the same widespread use. It was first designed to estimate 
the physiological status with no need for clinical resources 
and, although it can predict postoperative complications, 
it has a limited capability to predict cardiovascular compli-
cations. Moreover, there is a major problem related to poor 
reproducibility even among anesthesiologists24.
The Detsky Index11 is a modified version of the original 
risk index10. In his study, Detsky showed that the accuracy 
of the original method proposed by Goldman et al. had 
dropped from 81% to 69%. After inclusion of angina pec-
toris severity, previous myocardial infarction, critical aor-
tic stenosis, and alveolar pulmonary edema, the accuracy 
of the new index increased to 75%. Conversely, the authors 
observed many events in patients with low-risk scores 
(false negative) and a limited discrimination power in pa-
tients referred for vascular or other major surgery. Based 
upon the findings of Eagle et al.9 and Vanzetto et al.,25 the 
American College of Physicians (ACP) published a guide-
line for assessment and management of perioperative risk, 
suggesting the Modified Cardiac Index for stratification of 
all patients prior to surgery (Box 1)26,27. To minimize the 
limitations of this method, they recommended the use of 
a non-invasive cardiac ischemic test for individuals with a 
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low-risk of cardiovascular complications who were to un-
dergo vascular surgery and had more than two low-risk 
variables (Box 1). Although recommended by the ACP, 
the Detsky Index did not show any improvement in the 
prediction of cardiac risk when compared to other meth-
ods such as the Goldman, the ASA, or the New York Heart 
Association classification of angina28. Thus, despite the 
increased number of variables collected (and more com-
plicated to use), the ACP algorithm does not offer clear 
advantages over simpler methods for patient evaluation 
prior to noncardiac surgeries.
Comparing a new algorithm proposal with Detsky’s 
and Goldman’s, Lee et al. found even lower areas under 
the ROC curve for these two methods, and demonstrated a 
good accuracy for the prediction of cardiovascular events 
with a different system (Table 1)12. This approach is rec-
ommended by the new guidelines of the American Col-
lege of Cardiology, American Heart Association, and Eu-
ropean Society of Cardiology1,29. Although very simple to 
use, this new index, called the Revised Cardiac Risk Index 
(RCRI – Box 1), did not perform well for patients under-
going abdominal aortic aneurism (AAA) repair. A later 
validation of the RCRI showed limited value for the pre-
diction of cardiovascular mortality30.
Indeed, Bertges et al. found that the RCRI did not 
perform well for vascular surgery patients, consistently 
underestimating the composite cardiac complications 
across all risk groups. Therefore, the authors suggested 
American Society of Anesthesiologists Score  
(ASA Grade)23
Revised Cardiac Risk Index  
(Lee et al., 1999)12
I – Normal health patient
II – Patient with mild systemic disease
III – Patient with severe systemic disease
IV – Patient with severe systemic disease that is a constant 
threat to life
V – A moribund patient who is not expected to survive 
without the operation
1 – High risk type of surgery (intraperitoneal, intrathoracic, 
or suprainguinal vascular procedures)
2 – Ischemic heart disease (includes any of the following: 
history of myocardial infarction, history of positive exercise 
test, current complaint of chest pain, i.e., considered to be 
secondary to myocardial ischemia, use of nitrate therapy, 
or electrocardiography with pathologic Q waves)
3 – Congestive heart failure
4 – History of cerebrovascular disease
5 – Preoperative treatment with insulin
6 – Preoperative serum creatinine > 2.0 mg/dL
aClass I: 0 to 15 points (< 3% perioperative cardiac events); class II 20 to 30 points (3 to 15% perioperative cardiac events); class III: more than 
30 points (> 15% perioperative cardiac events). bClass I patients still do not reliably identify low risk patients for perioperative cardiac events. 
For these patients, when two or more low risk variables are present, consider referring for noninvasive testing. PAC, premature atrial complex.
Modiﬁed Cardiac Risk Index Indexa,11
Prior myocardial infarction
t-BTUJOGBSDUJPOXJUIJONPOUITQPJOUT
t-BTUJOGBSDUJPONPSFUIBONPOUITBHPQPJOUT
Arrhythmia
t3IZUINPUIFSUIBOTJOVTPSTJOVTXJUI1"$TQPJOUT
t.PSFUIBOmWFQSFNBUVSFWFOUSJDVMBSCFBUTQPJOUT
Angina pectoris
t$BOBEJBO"OHJOB$MBTTQPJOUT
t$BOBEJBO"OHJOB$MBTTQPJOUT
Poor general medical status: 5 points
tQ2 < 60 mm Hg, pCO2 > 50 mmHg, K < 3 mmol/L, 
blood urea nitrogen level > 50 mmol/L,  
creatinine 3mg/dL, bedridden
Alveolar pulmonary edema
t1VMNPOBSZFEFNBXJUIJOPOFXFFLQPJOUT
t1VMNPOBSZFEFNBBUBOZUJNFQPJOUT
Age > 70 years: 5 points
Suspected critical aortic stenosis: 20 points Emergency surgery: 10 points
Eagle and Vanzetto variables (low risk variables)b,9,25
Age > 70 years History of myocardial infarction
History of angina ST-segment ischemic abnormalities
during resting electrocardiography
Diabetes mellitus Hypertension with severe left ventricular hypertrophy
Q waves on electrocardiogram History of congestive heart failure
History of ventricular ectopy
Box 1 – Perioperative risk indexes
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a new method (Vascular Study Group of New England 
Cardiac Risk Index – VSG CRI) to predict cardiovascular 
complications. They added older age, chronic obstructive 
pulmonary disease, smoking, and long term β-blocker use 
as clinical variables31. This last method seems to reflect a 
higher risk population instead of merely reflecting the ef-
fect of the drug. With these modifications, the sensitivity, 
specificity, positive predictive value, and negative predic-
tive value were 68%, 62%, 11%, and 97%, respectively. 
In another study, the RCRI was inferior to the new pro-
posed score (Myocardial Infarction and Cardiac Arrest 
Score – MICA) across all studied patients, including AAA 
surgery32.
In a systematic review evaluating the ability to predict 
cardiac complications and mortality after major noncar-
diac surgery, the RCRI was only moderately good at dis-
criminating between low-risk versus high-risk patients 
for cardiac events33. The index was not adequate to predict 
cardiac events after vascular noncardiac surgery or to pre-
dict all-cause mortality33.
Moreover, the RCRI does not take age into account as 
a risk factor, although the same group of researchers later 
showed that age > 70 confers a higher risk for periopera-
tive cardiac and noncardiac complications4.
In summary, there are several algorithms for perioper-
ative risk estimation, with a wide variation of accuracy for 
the prediction of cardiovascular complications. The most 
important are shown in Table 2.
IMAGE METHODS
Echocardiography is the cornerstone of complementary 
cardiological evaluation and the most prescribed preopera-
tive noninvasive test34. It is readily available, with no con-
traindications and does not require intravenous injection, 
radioactive isotopes, or exposure to radiation. It provides 
information about cardiac dimensions, valve areas and 
function, abnormal communications between the left and 
right side, and calculation of cardiac output and ejection 
fraction. Despite all these advantages, the request of routine 
echocardiogram does not seem to improve survival or de-
tection of cardiac complications35, and may increase length 
of hospitalization after major elective noncardiac surgery36.
Coronary angiography (CA) is a well-established 
method for detecting coronary artery disease (CAD). 
It is invasive, but widely available, even in small hospi-
tals. Although there are no data regarding its use in the 
perioperative period, its indications, as well as revascu-
larization, are similar to angiography indications in non-
surgical settings1,29.
Cardiac stress tests are unequivocally the most often 
performed exams in patients referred to surgeries for de-
tection of CAD. In general, their use before elective major 
surgery is associated with improved survival in interme-
diate and high risk patients. This is probably due to the 
identification of those who could benefit from the intro-
duction of perioperative drug therapy such as β-blockers37. 
They have been used since the late 1980’s after the study 
by Eagle et al. demonstrated the benefit of dipyridamole-
thallium image scans for patients undergoing vascular op-
erations9. Their ability to predict cardiovascular complica-
tions is similar to that of clinical variables alone. However, 
when used together, thallium redistribution can separate 
intermediate risk patients into low- and high- risk groups 
with postoperative cardiac ischemic events rates of 3.2% 
and 29.6%, respectively9. These findings were confirmed 
by another study, which also found that the larger the isch-
emic area, the higher the probability of major cardiovas-
cular events25. Dobutamine-atropine echocardiography is 
a safe exam and lower in cost than scintigraphy. A positive 
result greatly increases the likelihood ratio (LR) of a peri-
operative cardiac event and, above all, it effectively identi-
fies a low-risk group with a very low incidence of compli-
cations38. Meta-analysis of published data also showed a 
better diagnostic performance of stress echocardiography 
in comparison to myocardial perfusion scintigraphy, with 
a negative LR of 0.23 vs. 0.44 and a positive LR of 4.09 
vs. 1.83 for detection of myocardial infarction or death, 
respectively39,40.
Recently, multislice computed tomography (MSCT) 
was shown to be useful in the screening for CAD with a 
high sensitivity and negative predictive value41. There is 
only one study evaluating the role of MSCT in patients re-
ferred for surgery and, although it is a retrospective study 
with serious limitations, it increased the capability of de-
tecting CAD when used together with scintigraphy. Fur-
thermore, when compared to CA, MSCT may identify pa-
tients at high-risk of cardiovascular events with the same 
rate, however at a lower cost42.
Reactive hyperemia is a vasodilatation of arterial vessels 
that occurs after a period of tissue ischemia and depends on 
local production of vasodilators. It is related to traditional 
cardiovascular risk factors and markers of inflammation43,44. 
Index Derivation Cohort (ROC area) Validation Cohort (ROC area)
0SJHJOBM$BSEJBD3JTL*OEFY 0.606 0.701
.PEJmFE$BSEJBD3JTL*OEFY 0.545 0.582
3FWJTFE$BSEJBD3JTL*OEFY 0.759 0.806
Table 1 – Area under the ROC curve for the perioperative cardiac indices (Based on Lee et al., 1999)12
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There are few studies on this technique for perioperative 
evaluation and results are controversial51,52. More research 
is needed to define its role in this field.
BIOMARKERS
In perioperative evaluation, new advances have recently been 
made, especially regarding biomarkers. Brain natriuretic 
peptide (BNP) and N-terminal pro-BNP (NT-proBNP) 
are produced by myocytes in response to stress and are 
important prognostic indicators of heart failure. They can 
identify patients with high-risk of cardiovascular com-
plications after noncardiac surgery despite the absence of 
inducible ischemia and low left ventricular ejection frac-
tion53-55, and they seem to be useful even in emergency 
noncardiac surgery56. Cuthbertson et al. demonstrated that 
a BNP > 40 pg.mL-1 has a sensitivity of 75% and a specific-
ity of 70% for predicting perioperative death or myocardial 
injury, and also performed better than the RCRI57. When 
meta-analyzed, elevated BNP or NT-proBNP were predic-
tors of adverse cardiovascular outcomes at 30 and 90 days 
and at over six months58-60. However, they are most useful 
to identify event-free survival and may not accurately iden-
tify mortality with a high degree of certainty – high nega-
tive predictive value and low positive predictive value59.
Score Year Advantages Disadvantages
ASA23 1963 Very simple to use Poor reproducibility, not developed for 
cardiovascular complications and does not 
take into account age and complexity of the 
operation
Goldman10 1977 Simple to use Developed before important advances in 
cardiology care
Detsky11 1986 Simple to use and well validated in other 
studies
Poor discriminative power for patients 
DMBTTJmFEBTJOUFSNFEJBUFSJTL%FWFMPQFE
before important advances in medicine
Charlson45,46 1987 Takes into account several risk factors not 
considered in other scores such as cancer, 
AIDS and liver disease. Validated in several 
populations
Originally used to predict mortality in general 
population. Used a high risk population 
admitted in a hospital. It was not validated 
in a large general population referred for 
noncardiac surgery
3$3*15 1999 Simple to use. Well validated in other 
populations
Poor performance for vascular surgeries 
(especially AAA repair) and for mortality 
prediction
Fleisher-Eagle47 2001 4JNQMFUPVTF4JNJMBSUP3$3*XJUIPVUIJTUPSZ
of cerebrovascular disease
The algorithm is a theoretical approach and 
was not validated in any population
EMAPO48 2007 Considers diseases not mentioned in previous 
guidelines and modern treatment options. 
4USBUJmFTQBUJFOUTJOUPmWFMFWFMTXJUIB
narrower interval of complications in each 
category
Complex execution due to the large number of 
items to consider. It was not validated in other 
studies and didn’t show any improvement 
compared to Detsky’s model
POSSUM49 1991 Allows comparative audit between different 
populations
/PUWBMJEBUFETQFDJmDBMMZGPSSJTLTUSBUJmDBUJPO
Seems to over predict death by a factor greater 
than two50 
74($3*31 2010 %FWFMPQFETQFDJmDBMMZGPSQBUJFOUTVOEFSHPJOH
vascular surgeries with a better performance 
UIBOUIF3$3*
Not validated in other populations
MICA32 2011 1FSGPSNFECFUUFSUIBO3$3*GPSNZPDBSEJBM
infarction and cardiac arrest. Takes into 
account the type of surgery
Developed from a surgical database without 
active search for cardiac complications. Not 
validated in other populations
"""BPSUJDBOFVSJTNSFQBJS"*%4BDRVJSFEJNNVOFEFmDJFODZTZOESPNF"4""NFSJDBO4PDJFUZPG"OFTUIFTJPMPHJTUT&."10NVMUJDFOUFS
study of perioperative evaluation; MICA, myocardial infarction or cardiac arrest score; POSSUM, physiological and operative severity score for 
FOVNFSBUJPOPGNPSUBMJUZBOENPSCJEJUZ74($3*WBTDVMBSTUVEZHSPVQPG/FX&OHMBOEDBSEJBDSJTLJOEFY3$3*3FWJTFE$BSEJBD3JTL*OEFY
Table 2 – Algorithms for perioperative risk evaluation
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Inflammatory markers such as C-reactive protein 
(CRP), which is related to atherogenesis and atheroscle-
rotic plaque instability, may identify patients with elevated 
coronary risk. However, their use in perioperative evalua-
tion has not been completely defined. In 2010, Choi et al. 
demonstrated that higher levels of CRP are associated with 
an increased risk of AMI, pulmonary edema, and cardio-
vascular death after major noncardiac surgery61. Yet, when 
associated with NT-proBNP, it increased the relative risk 
by threefold compared to classical algorithms for clinical 
events61. High-sensitivity CRP and fibrinogen were also 
recently studied, and at elevated levels they seem to inde-
pendently predict cerebral ischemic events after carotid 
endarterectomy in patients, whether symptomatic or not62.
ANKLE BRACHIAL INDEX
The ankle brachial index (ABI) is valuable for cardiovascu-
lar risk quantification and is perhaps the most promising 
source of information in the perioperative period, espe-
cially when compared to intima media thickness, coronary 
calcium score, and coronary and carotid atherosclerotic 
plaques63,64. In comparison with these methods, it is less 
expensive, faster, and feasible in office care, with a good 
acceptance by patients and little intra- and inter-observer 
variability65-67. The procedure is simple and can be carried 
out by a trained nurse or other health care professional64. 
It is easily done by measuring the systolic blood pressure 
(BP) with a portable Doppler ultrasound machine on each 
arm and on the dorsalis pedis and posterior tibial arteries of 
each ankle. The highest of the two arm pressures is selected, 
as is the highest of the two pressures of each ankle. The ABI 
is obtained by dividing the highest ankle BP in each leg by 
the highest arm pressure. The lowest value between the two 
indices (one for each leg) defines the risk of the patient. 
Normally, the BP is higher in the legs than in the arms68,69. 
Thus, it is expected that a normal ABI would be > 0.9 and 
≤ 1.3. Values > 1.3 suggest a non- compressible calcified ar-
tery in the ankle, thus the ABI is not reliable in this situ-
ation, because of unreliable BP measurements68,69. Values 
between 0.41 and 0.9 are associated with peripheral arterial 
disease (PAD) and severe PAD when ≤ 0.469. Asymptomatic 
patients with abnormal ABI and no prior cardiovascular 
disease, older than 70 years, or older than 50 years with an 
additional cardiac risk factor, should be treated as a patient 
with established PAD70. Furthermore, an abnormal ABI and 
PAD are associated with atherosclerosis in coronary and ce-
rebral arteries and a higher incidence of AMI, stroke, and 
cardiovascular and all-cause mortality63,70-72.
Although there is a close relationship between abnormal 
ABI and atherosclerosis, including in coronary arteries, the 
association of ABI with other cardiovascular scores has been 
poorly studied; however, it appears to be useful. In a recent 
meta-analysis the ABI has proven to be an independent 
cardiovascular risk factor, and when associated with the 
Framingham risk score (FRS), an abnormal result doubled 
all-cause mortality, cardiovascular mortality and major coro-
nary events in all groups of the FRS64. Further, after inclu-
sion of the ABI, 20% of men and 33% of women had their 
Framingham risk category changed. In women, this effect 
was mainly a change from low-risk to a high-risk category. In 
another study, the addition of ABI to traditional cardiovas-
cular risk factors such as diabetes, hypertension, smoking, 
and hypercholesterolemia improved the sensitivity, specific-
ity, and predictive values for a future cardiovascular event72.
Flu et al., recently demonstrated that an asymptomatic 
low ABI (< 0.9) increases the risk of perioperative myocar-
dial damage over twofold in patients undergoing AAA or 
carotid artery stenosis repair, even after adjusting for other 
cardiovascular risk factors73. Unfortunately, there are no 
data about the use of ABI in other patients referred for non-
vascular surgery, which comprises the majority of surgeries 
performed worldwide. Such use could add extensive infor-
mation about this population, especially if associated with 
well-validated perioperative cardiovascular risk scores.
CONCLUSIONS
With such conflicting information regarding the periop-
erative evaluation and its algorithms and exams, a cautious 
and accurate clinical evaluation of the patient’s cardiac risk 
is critical. The accuracy of methods available for predicting 
postoperative complications is better than random, but their 
performance is not ideal. Thus, measures and approaches 
that are widely available and easy to perform for the accu-
rate prediction of postoperative cardiovascular events are 
urgently needed.
The ideal risk prediction model would be one that is 
simple, reproducible, accurate, objective, and available to all 
patients74. Coronary calcium score, intima media thickness, 
pulse wave velocity, and ABI, which can predict a higher 
cardiovascular risk in the general population, appear to be 
promising for perioperative evaluation, adding important 
information to current guidelines and algorithms. The ABI, 
an easy to perform and widely available exam in office prac-
tice and points of care, appears to be the best approach and 
the most promising method, but evidence to support its use 
in the perioperative context, especially for patients undergo-
ing non-vascular surgeries is still needed.
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